LOS ANGELES—Soft Gel Technologies Inc. has been named the exclusive manufacturer of Next Pharmaceuticals' Sytrinol softgels, a blend of polymethoxylated flavones and tocotrienols promoting cardiovascular health.

 “We are pleased to partner with Next Pharmaceuticals in promoting Sytrinol softgels," said Steve Holtby, President and CEO of Soft Gel Technologies, Inc. “Manufacturing a heart-health product that is sourced from natural plant compounds, patented and backed by science aligns with our company’s mission for providing high-quality, clinically-studied branded ingredients."

Regan Miles, president of Next Pharmaceuticals, added, "SGTI is an ideal partner for Next Pharmaceuticals. Pairing their top quality delivery system with one of our premier ingredient will offer customers the best products for heart health."

Next Pharmaceuticals acquired Sytrinol last year from KGK Synergize.